ImmuneOncia aims to develop immuno-oncology therapeutics

to transform the standard of care in cancer treatment

  • About Us
  • History

History

The journey of ImmunOncia's innovation
and challenge continues.
  • 2025
    Business
    05
    KOSDAQ market listing on the KRX
    03
    Passed the preliminary review for KOSDAQ listing
    R&D
    07
    Completion of CSR for IMC-001's Phase 2 trial
    06
    Presentation of IMC-002-K102 Phase 1b data at ASCO 2025
    04
    Presentation of IMC-002 preclinical study results at AACR 2025
  • 2024
    Business
    04
    Passed the technology evaluation for KOSDAQ listing
    R&D
    06
    Presentation of IMC-001 Phase 2 results at EHA 2024
    05
    Presentation of IMC-002 Phase 1a results at ASCO 2024
    01
    Joint research agreement with Lunit for AI-powered biomarker identification
    01
    Co-development agreement for a bispecific antibody with Y-Biologics
  • 2023
    Business
    12
    Secured KRW 8 billion in a Series C funding round (from Yuhan Corporation)
    09
    Opening of the PIC Industry-Academia-Research Collaboration Center
    08
    Relocation of the Corporate R&D Center
    R&D
    08
    Approval of the IMC-002 Phase 1b IND from MFDS of Korea
    04
    Co-development agreement with NuclixBio for an mRNA drug
    02
    In-licensing of the NTIG® Platform from Progen
  • 2022
    R&D
    07
    Approval of the IMC-001 TMB-H Phase 2 IND from MFDS of Korea
    03
    Approval of the IMC-002 Phase 1a IND from MFDS of Korea
  • 2021
    Business
    12
    Secured KRW 24.5 billion in a Series B funding round (from Yuhan Corporation, Premier Partners, etc.)
    07
    Appointment of Heung Tae Kim as CEO
    R&D
    12
    IMC-201 selected as a multi-ministerial new drug development project by KDDF
    03
    Out-licensing of the IMC-002 to 3D Medicines for the Greater China region
  • 2020
    R&D
    11
    Co-development agreement with LegoChem Biosciences for an AIC
    05
    Approval of the IMC-001 Phase 2 IND for ENKTL from MFDS of Korea
    04
    Approval of the IMC-002 Phase 1 IND from FDA
  • established~2019
    Business
    19.02
    Secured KRW 45 billion in a Series A funding round (from Paratus Investment)
    18.01
    Establishment of the Corporate R&D Center
    16.09
    Establishment of the Corporation (JV)
    R&D
    19.09
    Co-development agreement for a bispecific antibody with Yuhan Corporation
    19.08
    IMC-002 selected as a multi-ministerial new drug development project by KDDF
    18.02
    Approval of the IMC-001 Phase 1 IND from MFDS of Korea